238 related articles for article (PubMed ID: 10737286)
1. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
Roth SH; Fleischmann RM; Burch FX; Dietz F; Bockow B; Rapoport RJ; Rutstein J; Lacouture PG
Arch Intern Med; 2000 Mar; 160(6):853-60. PubMed ID: 10737286
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
3. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.
Caldwell JR; Hale ME; Boyd RE; Hague JM; Iwan T; Shi M; Lacouture PG
J Rheumatol; 1999 Apr; 26(4):862-9. PubMed ID: 10229408
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
Hale ME; Fleischmann R; Salzman R; Wild J; Iwan T; Swanton RE; Kaiko RF; Lacouture PG
Clin J Pain; 1999 Sep; 15(3):179-83. PubMed ID: 10524470
[TBL] [Abstract][Full Text] [Related]
5. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial.
Markenson JA; Croft J; Zhang PG; Richards P
Clin J Pain; 2005; 21(6):524-35. PubMed ID: 16215338
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
[TBL] [Abstract][Full Text] [Related]
7. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
Kopecky EA; Vaughn B; Lagasse S; O'Connor M
Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain.
Friedmann N; Klutzaritz V; Webster L
J Opioid Manag; 2011; 7(3):193-202. PubMed ID: 21823550
[TBL] [Abstract][Full Text] [Related]
9. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(6):325-8, 331-3. PubMed ID: 17326594
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
Hale ME; Dvergsten C; Gimbel J
J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
[TBL] [Abstract][Full Text] [Related]
12. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(3):155-66. PubMed ID: 17319449
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
[TBL] [Abstract][Full Text] [Related]
15. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial.
Gimbel JS; Richards P; Portenoy RK
Neurology; 2003 Mar; 60(6):927-34. PubMed ID: 12654955
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
[TBL] [Abstract][Full Text] [Related]
18. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
[TBL] [Abstract][Full Text] [Related]
19. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.
Watson CP; Moulin D; Watt-Watson J; Gordon A; Eisenhoffer J
Pain; 2003 Sep; 105(1-2):71-8. PubMed ID: 14499422
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
